BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, May 21, 2012
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
5/18
cls
|
|
AMAG
Pharmaceuticals Inc. (NASDAQ:AMAG)
|
Ladenburg
Thalmann
|
Juan
Sanchez
|
Upgrade
|
Buy
(from neutral)
|
-1%
|
$13.14
|
|
Sanchez
set a $15 target, saying he believes AMAG is undervalued. He estimates iron
replacement therapy Feraheme ferumoxytol could be valued at $114-$126M by
applying a 2x multiple of revenues to his 2012 or 2013 projections. Thus,
Sanchez said AMAG could be "conservatively" valued at $317-$332M,
or $13.60-$14.30 per share after adding in estimated cash, by the end of
2013.
|
|
Ariad
Pharmaceuticals Inc. (NASDAQ:ARIA)
|
Summer
Street
|
Ling
Wang
|
Price
target
|
Buy
|
-6%
|
$15.98
|
|
Wang
raised her target to $21 from $16 after factoring in the value of AP26113,
which she believes has potential to become a front- or second-line anaplastic
lymphoma kinase (ALK)-targeting therapy for non-small cell lung cancer
(NSCLC). Wang anticipates preliminary data as early as next quarter for the
dual inhibitor of ALK and epidermal growth factor receptor (EGFR) from a
Phase I/II trial in NSCLC. She estimates peak global sales of about $2.7B for
AP26113.
|
171
words displayed of
555
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]